Software can be a medical device. Can it also be a drug?
Alcohol kills – and in this case, that could be a good thing.
Medtronic decides that Solitaire is best played with a partner.
Probiodrug changes its name to Vivoryon and expands its focus to include oncology, but insists that it is still first and foremost an Alzheimer’s company.
The company insists that its sickle cell disease therapy Endari still has a future, despite questionable efficacy and the approach of new treatments.
Blood tests could be faster and cheaper than tissue biopsies, but a Thermo Fisher exec argues they are likely to be more of an add-on technique.
Backed by big medtech including Medtronic, MD Start aims not just to incubate start-ups but to create new device companies from scratch.
A new player has entered the liquid biopsy game.
While praising Novartis for kickstarting the CAR-T revolution, the chief exec of Tmunity has no doubt where cell therapy’s development engine really lies.